Drugs / ZVS106e
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07241169 | Dec 2025 → Nov 2028 expected | Stargardt disease | Zhongshan Ophthalmic Center, Sun Yat-sen University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZVS106e | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07241169 ↗ |
| Action | Restore | “the Gene Replacement Drug ZVS106e” NCT07241169 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “The viral vectors used for both active ingredients are rAAV8” NCT07241169 ↗ |